For more than a century, Hodgkin disease (HD) has served as a paradigm
for developing modern oncology concepts. Yet the success of using radiotherapy,
chemotherapy, or both for cure of a formerly lethal disease has not come without
a price.1- 3 Even
though control of HD in early-stage and overall survival is approximately
90% at 10 years,4 survival is decreasing with
more years of observation, primarily due to a higher than expected number
of deaths from second malignancies. At 20 years after diagnosis, the cumulative
risk of developing second cancers is approximately 10%, exceeding the cumulative
risk of dying from the primary early-stage disease.4
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 20
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.